SPatial Heterogeneity of INtratumoral drug distribution
This study is investigating how certain breast cancer medications, specifically letrozole, Kisqali (also known as ribociclib), and anastrozole, spread throughout different areas of a tumour. These drugs are used for women with a common type of breast cancer called ER+ HER2- breast cancer. We want to see if the drugs reach all parts of the tumour effectively. By using special techniques, researchers will measure the amount of drug in different sections of the tumour. This information will help us understand if the treatments are working as well as they could and how we might improve them in the future. It’s part of a broader effort to make sure cancer treatments are as effective as possible for patients.
At a glance
What is this study about?
This research study, called SPatial Heterogeneity of INtratumoral drug distribution, is focused on understanding how specific breast cancer medicines spread within a tumour. When you take a medication, it travels through your body, but it’s important to know if enough of the drug actually gets to all the cancer cells. This study is looking at three medicines: letrozole, Kisqali (which is also known as ribociclib), and anastrozole. These drugs are commonly used to treat a type of breast cancer called ER+ HER2- breast cancer.
The main aim is to measure how much of these drugs are present in different parts of a tumour. Think of a tumour not as one uniform lump, but as having different sections, some of which might be harder for medicine to reach. By carefully checking drug levels in various areas using advanced laboratory techniques, we can learn if the treatments are reaching all the cancer cells as intended. This helps researchers figure out if the drugs are being delivered in the most effective way possible.
Beyond just looking at drug levels, the study also uses scans like MRI and ultrasound to get a detailed picture of the tumour and its surroundings. They also examine samples under a microscope to see how the tumour cells look and behave, and how the body’s immune system reacts to the treatment. All this information helps us get a clearer picture of how these cancer treatments work at a very detailed level, which could lead to better ways of treating breast cancer in the future.
Key takeaways
- The study helps us understand how breast cancer drugs reach tumours.
- It's for women with ER+ HER2- breast cancer taking specific medications.
- Researchers will measure drug levels in different parts of the tumour.
- Scans and tissue analysis will provide detailed information.
- This research aims to improve future breast cancer treatments.
Who may be eligible?
To be considered for this study, you would need to be a woman, at least 18 years old or older. There isn't an upper age limit mentioned, so older women might also be able to join.
This study is specifically for women who have a particular type of breast cancer called ER+ HER2- breast cancer. Your doctor will know if your cancer fits this description based on special tests.
You would also need to be taking specific medications for your breast cancer: either letrozole, Kisqali (also known as ribociclib), or anastrozole. The study focuses on how these particular drugs work within tumours.
- Are you female?
- Are you 18 years old or older?
- Do you have ER+ HER2- breast cancer?
- Are you currently taking letrozole, Kisqali (ribociclib), or anastrozole for your breast cancer?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
As this is a Phase IV study, it means the drugs are already approved and being used, and this study is gathering more information about them. Taking part would likely involve regular visits to a clinic for assessments. These assessments would probably include blood tests and possibly scans like MRI and ultrasound to keep an eye on your tumour. You would continue to take your prescribed medication (letrozole, Kisqali, or anastrozole) as usual. A key part of the study involves examining tumour tissue to measure drug levels within it, which would happen during your surgery for the breast cancer. We would also look at how your immune system responds to treatment. The study would follow your health for a period, which includes checking for any side effects from Kisqali up to 30 days after surgery. The total duration of your participation would be discussed with you by the research team.
Potential risks and benefits
Locations (1)
- —Netherlands
Common questions
What type of breast cancer is this study for?
It's for a common type of breast cancer called ER+ HER2- breast cancer.
What drugs are being studied?
The study looks at letrozole, Kisqali (ribociclib), and anastrozole.
Why is this study being done?
It helps us understand how breast cancer drugs spread inside tumours to make treatments more effective.
Will I have extra procedures if I join?
You might have additional scans or blood tests, and tumour tissue will be analysed during your planned surgery.
Can I leave the study if I change my mind?
Yes, you can leave the study at any time without it affecting your usual medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.